Pharmacogenetics-Guided De-Escalation of Dual Antiplatelet Therapy Based on CYP2C19 Testing in Patients After Acute Coronary Syndrome: Clinical Outcomes and Cost–Consequence Analysis
No statistically significant differences in bleeding or ischemic events were detected between genotype-guided de-escalation of DAPT based on CYP2C19 testing and standard practice in this trial, and the genotype-guided strategy was associated with a reduction in drug and testing costs.